---
title: "DFTX.US (DFTX.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/DFTX.US/news.md"
symbol: "DFTX.US"
name: "DFTX.US"
parent: "https://longbridge.com/en/quote/DFTX.US.md"
datetime: "2026-05-21T15:06:15.934Z"
locales:
  - [en](https://longbridge.com/en/quote/DFTX.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/DFTX.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/DFTX.US/news.md)
---

# DFTX.US (DFTX.US) — Related News

### [Definium posts May 2026 corporate presentation outlining Phase 3 DT120 readouts and $373.4M cash](https://longbridge.com/en/news/286904596.md)
*2026-05-19T11:33:00.000Z*
> Definium has released an updated corporate presentation detailing its Phase 3 DT120 ODT program, with three topline read

### [Watch live: Rethinking Psychedelic Treatment for America's Mental Health Crisis](https://longbridge.com/en/news/286901819.md)
*2026-05-19T11:13:15.000Z*
> A forum hosted by The Hill and Definium Therapeutics will discuss the potential of psychedelic treatments for mental hea

### [LifeSci Capital Remains a Buy on Definium Therapeutics (DFTX)](https://longbridge.com/en/news/286649305.md)
*2026-05-16T14:35:51.000Z*
> LifeSci Capital's Francois Brisebois has maintained a Buy rating on Definium Therapeutics (DFTX) with a price target of 

### [Definium Therapeutics (NASDAQ:DFTX) Issues Earnings Results](https://longbridge.com/en/news/285796112.md)
*2026-05-09T04:43:12.000Z*
> Definium Therapeutics (NASDAQ:DFTX) reported Q1 earnings of ($0.71) EPS, missing estimates of ($0.48) by ($0.23). The co

### [](https://longbridge.com/en/news/285762418.md)
*2026-05-08T17:51:32.000Z*
> Definium Therapeutics shares are trading lower after the company reported worse-than-expected Q1 EPS results. Also, Pipe

### [Definium Therapeutics | 8-K: FY2026 Q1 Revenue: USD 0](https://longbridge.com/en/news/285611285.md)
*2026-05-07T20:22:55.000Z*